The economic evidence indicates that pharmacotherapy (PT)-based smoking cessation interventions are likely to offer good value from public healthcare investment. Even with low rates of long-term abstinence, PT therapy is among the most cost-effective cancer control interventions available. The arguments for providing universal access to PT are strong, however perhaps not as important as ensuring that PT and/or other smoking cessation interventions and services are used by people who need them. In 2018, nearly every Canadian has access to one 12-week course of PT per year; however, this is not enough to maximize the public health benefits that could be gained from smoking cessation interventions. The evidence show that program participation and long-term abstinence rates can be maximized by including behavior-based supports, individualized program invitations, and adapting programs to local or disadvantaged context. Long-term abstinence and participation rates are the greatest drivers of cost-effectiveness. Improving these outcomes, therefore, is the best way to maximize public investment in smoking cessation. Canadian policy needs to consider this evidence in the design and implementation of programs and to collect health information data on a national level to track success rates.